JoVE Logo
Faculty Resource Center

Sign In

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

DOI :

10.3791/65068-v

September 15th, 2023

September 15th, 2023

861 Views

1Washington University of Medicine in St. Louis

We present a protocol that can be used to conduct therapeutic drug testing with patient-derived ovarian cancer organoids.

-- Views

Related Videos

article

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

article

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

article

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines

article

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models

article

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

article

Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish

article

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

article

Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids

article

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

article

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved